These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 18452482)

  • 1. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study.
    Iwasaki S; Ohira H; Nishiguchi S; Zeniya M; Kaneko S; Onji M; Ishibashi H; Sakaida I; Kuriyama S; Ichida T; Onishi S; Toda G;
    Hepatol Res; 2008 Jun; 38(6):557-64. PubMed ID: 18452482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate.
    Takano K; Saeki C; Oikawa T; Hidaka A; Mizuno Y; Ishida J; Takakura K; Nakano M; Torisu Y; Amano K; Ishikawa T; Zeniya M; Tsubota A; Saruta M
    J Gastroenterol Hepatol; 2020 Apr; 35(4):663-672. PubMed ID: 31677185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.
    Hosonuma K; Sato K; Yamazaki Y; Yanagisawa M; Hashizume H; Horiguchi N; Kakizaki S; Kusano M; Yamada M
    Am J Gastroenterol; 2015 Mar; 110(3):423-31. PubMed ID: 25732417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
    Dohmen K; Tanaka H; Haruno M
    Fukuoka Igaku Zasshi; 2013 Oct; 104(10):350-61. PubMed ID: 24511666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid.
    Takeuchi Y; Ikeda F; Fujioka S; Takaki T; Osawa T; Yasunaka T; Miyake Y; Takaki A; Iwasaki Y; Kobashi H; Yamamoto K; Itoshima T
    J Gastroenterol Hepatol; 2011 Sep; 26(9):1395-401. PubMed ID: 21443659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA.
    Tanaka A; Hirohara J; Nakanuma Y; Tsubouchi H; Takikawa H
    J Gastroenterol; 2015 Jun; 50(6):675-82. PubMed ID: 25239675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.
    Tanaka A; Hirohara J; Nakano T; Matsumoto K; Chazouillères O; Takikawa H; Hansen BE; Carrat F; Corpechot C
    J Hepatol; 2021 Sep; 75(3):565-571. PubMed ID: 33882268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis.
    Honda A; Tanaka A; Kaneko T; Komori A; Abe M; Inao M; Namisaki T; Hashimoto N; Kawata K; Takahashi A; Ninomiya M; Kang JH; Arakawa M; Yamagiwa S; Joshita S; Umemura T; Sato K; Kaneko A; Kikuchi K; Itakura J; Nomura T; Kakisaka K; Fujii H; Kawada N; Takikawa Y; Masaki T; Ohira H; Mochida S; Yoshiji H; Iimuro S; Matsuzaki Y; Takikawa H;
    Hepatology; 2019 Dec; 70(6):2035-2046. PubMed ID: 30737815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up.
    Sorda JA; González Ballerga E; Barreyro FJ; Avagnina A; Carballo P; Paes de Lima A; Daruich J
    Aliment Pharmacol Ther; 2021 Nov; 54(9):1202-1212. PubMed ID: 34587309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis.
    Itakura J; Izumi N; Nishimura Y; Inoue K; Ueda K; Nakanishi H; Tsuchiya K; Hamano K; Asahina Y; Kurosaki M; Uchihara M; Miyake S
    Hepatol Res; 2004 Aug; 29(4):216-222. PubMed ID: 15288014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Bezafibrate Alone or in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis.
    Khakoo NS; Sultan S; Reynolds JM; Levy C
    Dig Dis Sci; 2023 Apr; 68(4):1559-1573. PubMed ID: 36180756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.
    Hazzan R; Tur-Kaspa R
    J Clin Gastroenterol; 2010; 44(5):371-3. PubMed ID: 19881358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of bezafibrate and ursodeoxycholic acid in patients with primary biliary cholangitis: a meta-analysis of randomized controlled trials.
    Agrawal R; Majeed M; Attar BM; Omar YA; Mbachi C; Wang Y; Flores E; Shaqib S; Wang Y; Udechukwu V; Demetria M; Gandhi S
    Ann Gastroenterol; 2019; 32(5):489-497. PubMed ID: 31474796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ursodeoxycholic acid combined with bezafibrate in the treatment of refractory primary biliary cholangitis: a meta-analysis].
    Feng BL; Yu HH; Shen W
    Zhonghua Gan Zang Bing Za Zhi; 2019 Apr; 27(4):304-311. PubMed ID: 31082343
    [No Abstract]   [Full Text] [Related]  

  • 15. Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: A meta-analysis.
    Zhang Y; Chen K; Dai W; Xia Y; Wang F; Shen M; Cheng P; Wang C; Yang J; Zhu R; Zhang H; Li J; Zheng Y; Wang J; Lu J; Zhou Y; Guo C
    Hepatol Res; 2015 Jan; 45(1):48-58. PubMed ID: 24934524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.
    Honda A; Ikegami T; Nakamuta M; Miyazaki T; Iwamoto J; Hirayama T; Saito Y; Takikawa H; Imawari M; Matsuzaki Y
    Hepatology; 2013 May; 57(5):1931-41. PubMed ID: 22911624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bezafibrate treatment: a new medical approach for PBC patients?
    Kanda T; Yokosuka O; Imazeki F; Saisho H
    J Gastroenterol; 2003; 38(6):573-8. PubMed ID: 12825134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bezafibrate for primary biliary cirrhosis.
    Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2012 Jan; 1():CD009145. PubMed ID: 22259000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study.
    Cançado GGL; Couto CA; Guedes LV; Braga MH; Terrabuio DRB; Cançado ELR; Ferraz MLG; Villela-Nogueira CA; Nardelli MJ; Faria LC; de Oliveira EMG; Rotman V; Mazo DFC; Borges VFAE; Mendes LSC; Codes L; Pessoa MG; Signorelli IV; Levy C; Bittencourt PL
    Front Pharmacol; 2021; 12():818089. PubMed ID: 35126149
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
    Reig A; Sesé P; Parés A
    Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.